Cholinesterase Inhibitors for Treating Inflammation

1 . A method of treating a subject with a cytokine-mediated inflammatory disorder, comprising:
 administering to the subject a pharmaceutically acceptable cholinesterase inhibitor in an amount sufficient to reduce the level of a proinflammatory cytokine, provided that the inhibitor is not galantamine, wherein the inflammatory disorder is asthma.   
     
     
         2 - 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the cholinesterase inhibitor is at least one selected from the group consisting of tacrine, a tacrine analog, fasciculin, metrifonate, heptyl-physostigmine, norpyridostigmine, nomeostigmine, huperzine A or an analogue thereof, physostigmine, heptylphysostigmine, velnacrine, citicoline, donepezil, 7-methoxytacrine, eptastigmine, icopezil, ipidacrine, zifrosilone, anseculin, suronacrine, linopiridine, rivastigmine, neostigmine, edrophonium, deinacarium, ambenonium, arecoline, xanomeline, subcomeline, cevimeline, alvameline, milameline, talsaclidine, and compounds of formulae (XVIII)-(XXI): 
       
         
           
           
               
               
           
         
       
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 1  wherein the cholinesterase inhibitor is at least 95% pure by weight. 
     
     
         19 . The method of  claim 16  wherein the cholinesterase inhibitor is tacrine. 
     
     
         20 . The method of  claim 16  wherein the cholinesterase inhibitor is huperzine A. 
     
     
         21 . The method of  claim 16  wherein the cholinesterase inhibitor is neostigmine. 
     
     
         22 . The method of  claim 16  wherein the cholinesterase inhibitor is physostigmine. 
     
     
         23 . A method of reducing proinflammatory cytokine levels in a subject in need of such reduction, comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine, wherein the subject suffers from asthma. 
     
     
         24 . A method of treating a subject suffering from a disorder, comprising:
 administering to the subject a therapeutically effective amount of pharmaceutically acceptable cholinesterase inhibitor, wherein the disorder is asthma, provided that the inhibitor is not galantamine.